AC
KERX

Amici Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Amici Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-62,750
Closed -$221K – 151
2015
Q3 		$221K Buy
+62,750
New +$420K 0.01% 135

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Amici Capital's KERX Position: Q4 2015 in Review

Amici Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 62,750 shares — an estimated $221K sold.

Amici Capital first reported a position in KERX in Q3 2015 and held it in 1 quarter. The position peaked at $221K in Q3 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

  • Amici Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Amici Capital sold 62,750 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $221K.
  • Amici Capital first reported a position in Keryx Biopharmaceuticals Inc in Q3 2015 and held it in 1 quarter.
  • Amici Capital's Keryx Biopharmaceuticals Inc position peaked at $221K in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on Amici Capital's 13F filing for Q4 2015, filed 16 Feb 2016.